Condition
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Total Trials
6
Recruiting
3
Active
6
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (3)
P 3 (1)
Trial Status
Recruiting3
Active Not Recruiting3
Clinical Trials (6)
Showing 6 of 6 trials
NCT07023315Phase 3RecruitingPrimary
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
NCT06693128Phase 2Active Not RecruitingPrimary
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
NCT04208347Phase 2Active Not RecruitingPrimary
Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT06605404Recruiting
Pan-tumor MRD Study
NCT07026149Phase 2RecruitingPrimary
Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer
NCT05128487Phase 1Active Not Recruiting
A Study of NDI 1150-101 in Patients With Solid Tumors
Showing all 6 trials